Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766000 | 1.00 | ALDH1A1 (0.45) | ALDH1A1MTNR1AMTNR1BMAPTPTGS2 | |
| SCHEMBL4378947 | 1.00 | ALDH1A1 (0.45) | ALDH1A1MTNR1AMTNR1BMAPTPTGS2 | |
| SCHEMBL1668685 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MTNR1AMTNR1BMAPTPTGS2 | |
| SCHEMBL6249964 | 0.82 | SLC22A6 (0.39) | ALDH1A1MAPTPTGS2SMN1; SMN2SLC22A6 | |
| SCHEMBL20230310 | 0.82 | GNPAT (0.56) | ALDH1A1MAPTPTGS2KDM4ETHRB | |
| SCHEMBL18395913 | 0.81 | MTNR1A (0.46) | ALDH1A1MTNR1AMTNR1BMAPTPTGS2 | |
| SCHEMBL18394981 | 0.81 | MTNR1A (0.46) | ALDH1A1MTNR1AMTNR1BMAPTPTGS2 | |
| SCHEMBL18394986 | 0.81 | MTNR1A (0.46) | ALDH1A1MTNR1AMTNR1BMAPTPTGS2 | |
| SCHEMBL18395917 | 0.81 | MTNR1A (0.46) | ALDH1A1MTNR1AMTNR1BMAPTPTGS2 | |
| SCHEMBL10055894 | 0.78 | ITGB3 (0.43) | ALDH1A1MAPTPTGS2SLC22A6ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | claimed |
| CN-112300017-B | Racemization preparation method of chiral beta-amino acid and derivative thereof | 浙江九洲药业股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-112300017-A | Racemization preparation method of chiral beta-amino acid and derivative thereof | 浙江九洲药业股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9271993-B2 | Treatment of bacterial infectious diseases | UNIVERSITY OF ZURICH (CH) | 2016-03-01 | — | — | US | disclosed |
| EP-2616079-B1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | UNIV ZÜRICH (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-1620294-A | Pyrimidine A2BSelective antagonist compounds, their synthesis and use | OSI PHARM INC (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20040186314-A1 | Process for the preparation of enantiomerically enriched n-acyl-beta-amino acid derivatives by enantioselective hydrogenation of the corresponding (z)-enamides | MALAN CHRISTOPHE GUILLAUME (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1421059-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED N-ACYL-BETA-AMINO ACID DERIVATIVES BY ENANTIOSELECTIVE HYDROGENATION OF THE CORRESPONDING (Z)-ENAMIDES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003016264-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED N-ACYL-BETA-AMINO ACID DERIVATIVES BY ENANTIOSELECTIVE HYDROGENATION OF THE CORRESPONDING (Z)-ENAMIDES | CHIROTECH TECHNOLOGY LIMITED (GB) | 2003-02-27 | — | — | WO | disclosed |
| US-6399787-B1 | TRANSITION METAL COMPLEX | PENN STATE RESEARCH FOUNDATION | 2002-06-04 | — | — | US | disclosed |
| WO-1999059721-A1 | CATALYTIC ASYMMETRIC HYDROGENATION, HYDROFORMYLATION, AND HYDROVINYLATION VIA TRANSITION METAL CATALYSTS WITH PHOSPHINES AND PHOSPHITES | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5518903-A | HYDROLYSIS OF ESTER | CHISSO CORPORATION (JP) | 1996-05-21 | — | — | US | disclosed |
| EP-0695296-A1 | 3-(HETERO)ARYLOXY(THIO) CARBOXYLIC ACID DERIVATIVES, METHOD OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994025443-A1 | 3-(HETERO)ARYLOXY(THIO) CARBOXYLIC ACID DERIVATIVES, METHOD OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ALDH1A1 283/4885MTNR1A 995/4885MTNR1B 750/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ALDH1A1 283/4885MTNR1A 995/4885MTNR1B 750/4885 |
| US-20040186314-A1 | Process for the preparation of enantiomerically enriched n-acyl-beta-amino acid derivatives by enantioselective hydrogenation of the corresponding (z)-enamides | EEF1D, ADH5, HRH3 | ALDH1A1 1084/4885MTNR1A 2147/4885MTNR1B 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.